Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy

Diagnostic Microbiology and Infectious Disease

Volumn 75, Issue 2, 2013, Pages 144-149

  Neofytos, Dionissios ^a   Lu, Kit ^a,b   Hatfield Seung, Amy ^c   Blackford, Amanda ^d   Marr, Kieren A ^a,d   Treadway, Suzanne ^a   Ostrander, Darin ^a   Nussenblatt, Veronique ^a   Karp, Judith ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute myeloid leukemia; Epidemiology; Invasive fungal infections; Risk factors; Survival

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CYTARABINE; DAUNORUBICIN; ECHINOCANDIN; ETOPOSIDE; FLAVOPIRIDOL; FLUCONAZOLE; MITOXANTRONE; PYRROLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANDIDEMIA; CAUSE OF DEATH; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG EFFECT; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION PREVENTION; INFECTION RISK; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MOULD; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SYSTEMIC MYCOSIS;

ADULT; AGED; FEMALE; FEVER; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84872489966     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.10.001     Document Type: Article

References (22)

1. Auberger J., Lass-Florl C., et al. Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 2008, 88(5):508-515.
2. Boersma W.G., Erjavec Z., et al. Bronchoscopic diagnosis of pulmonary infiltrates in granulocytopenic patients with hematologic malignancies: BAL versus PSB and PBAL. Respir Med 2007, 101(2):317-325.
3. Bow E.J., Loewen R., et al. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995, 21(2):361-369.
4. Cordonnier C., Pautas C., et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009, 48(8):1042-1051.
5. Cornely O.A., Maertens J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356(4):348-359.
6. De Pauw B., Walsh T.J., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46(12):1813-1821.
7. Freifeld A.G., Bow E.J., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52(4):e56-e93.
8. Hahn-Ast C., Glasmacher A., et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother 2010, 65(4):761-768.
9. Hammond S.P., Marty F.M., et al. Invasive fungal disease in patients treated for newly diagnosed acute leukemia. Am J Hematol 2010, 85(9):695-699.
10. Horvath J.A., Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996, 100(2):171-178.
11. Karp J.E., Blackford A., et al. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res 2010, 34(7):877-882.
12. Karp J.E., Smith B.D., et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 2007, 13(15 Pt 1):4467-4473.
13. Malagola M., Peli A., et al. Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases. Eur J Haematol 2008, 81(5):354-363.
14. Michallet M., Sobh M., et al. Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole. Med Mycol 2011, 49(7):681-687.
15. Muhlemann K., Wenger C., et al. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005, 19(4):545-550.
16. Nucci M., Nouer S.A., et al. Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis 2010, 51(11):1273-1280.
17. Peikert T., Rana S., et al. Safety, diagnostic yield, and therapeutic implications of flexible bronchoscopy in patients with febrile neutropenia and pulmonary infiltrates. Mayo Clin Proc 2005, 80(11):1414-1420.
18. Rotstein C., Bow E.J., et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999, 28(2):331-340.
19. Vehreschild J.J., Bohme A., et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007, 55(5):445-449.
20. Vehreschild J.J., Ruping M.J., et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother 2010, 65(7):1466-1471.
21. Winston D.J., Chandrasekar P.H., et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993, 118(7):495-503.
22. Yu V.L., Muder R.R., et al. Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study. Am J Med 1986, 81(2):249-254.